全文获取类型
收费全文 | 3867篇 |
免费 | 273篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 93篇 |
妇产科学 | 79篇 |
基础医学 | 575篇 |
口腔科学 | 112篇 |
临床医学 | 421篇 |
内科学 | 797篇 |
皮肤病学 | 82篇 |
神经病学 | 229篇 |
特种医学 | 116篇 |
外国民族医学 | 2篇 |
外科学 | 562篇 |
综合类 | 58篇 |
预防医学 | 273篇 |
眼科学 | 114篇 |
药学 | 318篇 |
中国医学 | 93篇 |
肿瘤学 | 207篇 |
出版年
2024年 | 4篇 |
2023年 | 49篇 |
2022年 | 130篇 |
2021年 | 180篇 |
2020年 | 134篇 |
2019年 | 175篇 |
2018年 | 209篇 |
2017年 | 141篇 |
2016年 | 197篇 |
2015年 | 160篇 |
2014年 | 225篇 |
2013年 | 273篇 |
2012年 | 450篇 |
2011年 | 365篇 |
2010年 | 223篇 |
2009年 | 134篇 |
2008年 | 209篇 |
2007年 | 221篇 |
2006年 | 170篇 |
2005年 | 138篇 |
2004年 | 98篇 |
2003年 | 64篇 |
2002年 | 72篇 |
2001年 | 9篇 |
2000年 | 4篇 |
1999年 | 8篇 |
1998年 | 16篇 |
1997年 | 4篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 7篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1990年 | 3篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1973年 | 6篇 |
1879年 | 1篇 |
排序方式: 共有4170条查询结果,搜索用时 0 毫秒
91.
Mohammad Navid Soltani Rad Somayeh Behrouz Elham Zarenezhad Mohammad Hossein Moslemin Ali Zarenezhad Mehdi Mardkhoshnood Marzieh Behrouz Saeid Rostami 《Medicinal chemistry research》2014,23(8):3810-3822
The syntheses and biological studies of O-oxime ethers having α-amino acid residues as new analogs of IPS-339 have been described. In this synthesis, the reaction of fluorene and/or benzophenone O-oxime with epichlorohydrin or epibromohydrin afforded the corresponding O-oxime ether adducts. The N-alkylation of amino acid with O-oxime ether adducts led to synthesis of new analogs of IPS-339. The products were examined for their cardiovascular property. It was demonstrated that 2-(3-(9H-fluoren-9-ylideneaminooxy)-2-hydroxypropylamino)-3-methyl-butanoic acid as the most potent compound substantially reduces the heart rate of dogs. Compounds were also evaluated for their in vitro antibacterial activity against some Gram-negative and Gram-positive bacteria. The antibacterial screening proved the considerable antibacterial activity against both groups of bacteria. The docking analysis demonstrated the appropriate fitting of 2-(3-(9H-fluoren-9-ylideneaminooxy)-2-hydroxy-propylamino)-3-methyl-butanoic acid in human β2-adrenergic receptor active site. Potential drug toxicity for some active compounds has also been predicted. 相似文献
92.
93.
Mohammad Hossein Karimi Salimeh Ebrahimnezhad Mandana Namayandeh Zahra Amirghofran 《Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences》2014,22(1):28
Background
Cichorium intybus is a medicinal plant commonly used in traditional medicine for its benefits in immune-madiated disorders. There are several evidences showing that C. intybus can modulate immune responses. In the present study we have investigated the effects of the ethanolic root extract of this plant on the immune system by targeting dendritic cells (DCs). For this purpose, phenotypic and functional maturity of murine DCs after treatment with the extract was analyzed by flow cytometry and mixed lymphocyte reaction (MLR) assay.Results
C. intybus did not change the expression of CD40, CD86 and MHC-II molecules as important co-stimulatory markers on DCs compared to the control, indicating that it could not promote DCs phenotypic maturation. Treatment of DCs with lower concentrations of the extract resulted in an increased production of IL-12 by these cells with no change in IL-10 release. The capacity of treated DCs to stimulate allogenic T cells proliferation and cytokines secretion was examined in the co-cuture of these cells with T cells in MLR. C. intybus at higher concentrations inhibited proliferation of allogenic T cells and in lower concentrations changed the level of cytokines such that IL-4 decreased and IFN-γ increased.Conclusions
These results indicated that C. intybus extract at higher concentrations can inhibit T cell stimulating activity of DCs, whereas at lower concentrations can modulate cytokine secretion toward a Th1 pattern. These data may in part explain the traditional use of this plant in treatment of immune-mediated disorders. 相似文献94.
Hossein Hosseinzadeh Soghra Mehri Ali Heshmati Mohammad Ramezani Amirhossein Sahebkar Khalil Abnous 《Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences》2014,22(1):5
Background
Traditional drug discovery approaches are mainly relied on the observed phenotypic changes following administration of a plant extract, drug candidate or natural product. Recently, target-based approaches are becoming more popular. The present study aimed to identify the cellular targets of crocin, the bioactive dietary carotenoid present in saffron, using an affinity-based method.Methods
Heart, kidney and brain tissues of BALB/c mice were homogenized and extracted for the experiments. Target deconvolution was carried out by first passing cell lysate through an affinity column prepared by covalently attaching crocin to agarose beads. Isolated proteins were separated on a 2D gel, trypsinized in situ and identified by MALDI-TOF/TOF mass spectrometry. MASCOT search engine was used to analyze Mass Data.Results
Part of proteome that physically interacts with crocin was found to consist of beta-actin-like protein 2, cytochrome b-c1 complex subunit 1, ATP synthase subunit beta, tubulin beta-3 chain, tubulin beta-6 chain, 14-3-3 protein beta/alpha, V-type proton ATPase catalytic subunitA, 60 kDa heat shock protein, creatine kinase b-type, peroxiredoxin-2, cytochrome b-c1 complex subunit 2, acetyl-coA acetyltransferase, cytochrome c1, proteasome subunit alpha type-6 and proteasome subunit alpha type-4.Conclusion
The present findings revealed that crocin physically binds to a wide range of cellular proteins such as structural proteins, membrane transporters, and enzymes involved in ATP and redox homeostasis and signal transduction. 相似文献95.
Leah H. Rubin C. Sue Carter Jeffrey R. Bishop Hossein Pournajafi-Nazarloo Lauren L. Drogos S. Kristian Hill Anthony C. Ruocco Sarah K. Keedy James L. Reilly Matcheri S. Keshavan Godfrey D. Pearlson Carol A. Tamminga Elliot S. Gershon John A. Sweeney 《Schizophrenia bulletin》2014,40(6):1374-1384
Oxytocin (OT) and arginine vasopressin (AVP) exert robust influence on social affiliation and specific cognitive processes in healthy individuals. Abnormalities in these neuroendocrine systems have been observed in psychotic disorders, but their relation to impairments in behavioral domains that these endocrines modulate is not well understood. We compared abnormalities of OT and AVP serum concentrations in probands with schizophrenia (n = 57), schizoaffective disorder (n = 34), and psychotic bipolar disorder (n = 75); their first-degree relatives without a history of psychosis (n = 61, 43, 91, respectively); and healthy controls (n = 66) and examined their association with emotion processing and cognition. AVP levels were lower in schizophrenia (P = .002) and bipolar probands (P = .03) and in relatives of schizophrenia probands (P = .002) compared with controls. OT levels did not differ between groups. Familiality estimates were robust for OT (h
2 = 0.79, P = 3.97e−15) and AVP (h
2 = 0.78, P = 3.93e−11). Higher levels of OT were associated with better emotion recognition (β = 0.40, P < .001) and general neuropsychological function (β = 0.26, P = .04) in healthy controls as expected but not in any proband or relative group. In schizophrenia, higher OT levels were related to greater positive symptom severity. The dissociation of OT levels and behavioral function in all proband and relative groups suggests that risk and illness factors associated with psychotic disorders are not related to reduced OT levels but to a disruption in the ability of physiological levels of OT to modulate social cognition and neuropsychological function. Decreased AVP levels may be a marker of biological vulnerability in schizophrenia because alterations were seen in probands and relatives, and familiality was high.Key words: oxytocin, vasopressin, schizophrenia, bipolar disorder, emotion recognition 相似文献
96.
97.
Mehdi Farokhnia Maryam Sabzabadi Hossein Pourmahmoud Mohammad-Reza Khodaie-Ardakani Seyed-Mohammad-Reza Hosseini Habibeh Yekehtaz Mina Tabrizi Farzin Rezaei Bahman Salehi Shahin Akhondzadeh 《Psychopharmacology》2014,231(3):533-542
Rationale
Several recent studies have focused on glutamate modulating agents for symptoms relief in schizophrenia, especially negative symptoms which are resistant to conventional therapies.Objectives
We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia.Methods
In this randomized double-blind placebo-controlled parallel-group study, 50 patients with chronic schizophrenia and a score of ≥20 on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. Participants were equally randomized to receive riluzole (100 mg/day) or placebo in addition to risperidone (up to 6 mg/day) for 8 weeks. Participants were rated by PANSS every 2 weeks. The primary outcome of this study was the difference in the decrease of PANSS negative subscale score from baseline to the study endpoint between the two groups.Results
By the study endpoint, riluzole-treated patients showed significantly greater improvement in the negative symptoms (P?<?0.001) as well as the PANSS total and general psychopathology subscale scores (P?=?0.001 and P?<?0.001; respectively) compared to the placebo group. Treatment group was the only significant predictor of changes in negative symptom in this trial (β?=??0.56, P?<?0.001). No significant difference was observed between two groups in the frequency of side effects.Conclusion
These preliminary findings suggest that riluzole may be a safe and effective medication for the treatment of negative symptoms in patients with chronic schizophrenia. Further research and replication of study findings is warranted.Clinical trial registry name and registration number
Iranian registry of clinical trials www.irct.ir, IRCT201107281556N26 相似文献98.
Iman Karimzadeh Hossein Khalili Simin Dashti-Khavidaki Ramezanali Sharifian Alireza Abdollahi Mehrdad Hasibi Zahra Khazaeipour Shadi Farsaei 《European journal of clinical pharmacology》2014,70(4):399-408
Purpose
The aim of this study was to evaluate the effectiveness of oral n-acetyl cysteine, as a potential nephroprotective agent, in preventing and/or attenuating amphotericin B-induced electrolytes imbalances.Methods
During a one year period, patients were to receive conventional amphotericin b for any indication for at least one week and were randomly allocated to receive either placebo or 600 mg oral n-acetyl cysteine twice daily during the treatment course of amphotericin b. Demographic and clinical data of the study population were gathered. Different aspects of amphotericin b nephrotoxicity including decrease of glomerular filtration rate, hypokalemia, hypomagnesemia, renal magnesium and potassium wasting were assessed. Each patient was monitored for any adverse reaction to n-acetyl cysteine. Sixteen and 14 patients in the n-acetyl cysteine and placebo groups completed the study, 3incidences of hypokalemia (75 % versus 70 %; P?=?0.724) and hypomagnesemia (30 % versus 20 %; P?=?0.468) did not differ significantly between placebo and NAC groups, respectively. Although the rate of AmB nephrotoxicity was higher in the placebo than in the NAC group (60 % versus 40 %), this difference was not statistically significant (P?=?0.209) even after adjusting for probable associated factors of amphotericin b nephrotoxicity (P?=?0.206). The incidence as well as time of onset of electrolyte abnormalities also did not differ significantly between placebo and n-acetyl cysteine groups. About 44 % of n-acetyl cysteine recipients experienced new onset nausea and a mild unpleasant taste during the study.Conclusion
Oral n-acetyl cysteine during the amphotericin B treatment course was not significantly effective in preventing or mitigating different features of its nephrotoxicity including decrease of glomerular filtration rate, hypokalemia, hypomagnesemia, and renal potassium as well as magnesium wasting. 相似文献99.
Atefeh Jafari Hossein Khalili Simin Dashti-Khavidaki 《European journal of clinical pharmacology》2014,70(9):1029-1040
Objective
In this study, data regarding epidemiology, risk factors, pathogenesis and outcome of tenofovir-induced nephrotoxicity will be reviewed, and current and future approaches for prevention will be discussed.Method
The data were collected by searching Scopus, PubMed, Medline, Science direct, Clinical trials and Cochrane database systematic reviews. The keywords used as search terms were “Tenofovir”, “TDF”, “NRTI”, “Nephrotoxicity”, “Renal failure”, “Kidney damage”, “HIV” and “AIDS”.Results and conclusion
Several predisposing factors including elevated baseline SCr, concomitant nephrotoxic medications, low body weight, advanced age, tenofovir disoproxil fumarate (TDF) dose and duration of treatment and lower CD4 cell count were identified as risk factors for development of TDF-induced nephrotoxicity. Cellular accumulation through increased entry from the human organic anion transporters and decreased efflux into tubular lumen is main mechanism of nucleotide analogue antiviral induced nephrotoxicity. Renal function assessment and monitoring at baseline and during TDF treatment are the main approach of prevention of TDF-induced nephrotoxicity. Rosiglitazone may be helpful in patients presenting with TDF-induced nephrotoxicity. Pretreatment with melatonin prevented all known histological changes in proximal tubular mitochondira induced by TDF. Use of antioxidants with mitochondria-targeted properties such as MitoQ or Mito-CP may prevent proximal tubular mitochondrial against TDF damage. Vitamin E, ebselen, lipoic acid, plastoquinone, nitroxides, SOD enzyme mimetics, Szeto-Schiller (SS) peptides, and quercetin are other potential agents for prevention of TDF-induced nephrotoxicity. However, data regarding effectiveness of nephroprotective agents against TDF-induced nephrotoxicity are not conclusive. Before extrapolation of the preclinical evidence to clinical practice, these evidence should be confirmed in future human studies. 相似文献100.
Hasti Rouhani Nima Sepehri Hamed Montazeri Mohammad Reza Khoshayand Mohammad Hossein Ghahremani Seyed Nasser Ostad Fatemeh Atyabi Rassoul Dinarvand 《Pharmaceutical research》2014,31(8):2124-2139